poisar

Stocks · News reference

Zymeworks Presents Phase 1 Clinical Data for ZW191 at ESMO Congress 2026

Fiscal.ai

Zymeworks reported new clinical data from its Phase 1 study of ZW191, an antibody-drug conjugate targeting folate receptor alpha, showing anti-tumor activity in platinum-resistant ovarian cancer.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Zymeworks Inc. (ZYME)

    Filed: 2026-11-16 AccNo: 0001937653-26-000070 Size: 197 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits